Published on December 18, 2009 at 4:31 AM
Liquidia Technologies today announced it will receive approximately $3
million in funding from the U.S. Commerce Department’s National
Institute of Standards and Technology (NIST) to further develop and
scale-up the company’s PRINT manufacturing process. As part of its
Technology Innovation Program (TIP), NIST announced it will fund new
cost-sharing projects to support innovative technologies that address
critical national needs.
“We are very excited to have been selected by NIST as one of the 20
projects to receive funding through the TIP program,” said Tom
Templeman, Senior Vice President, Integrated Supply Chain at Liquidia.
“This investment will support our continued development of PRINT
manufacturing, which will allow us to develop clinically relevant
quantities of particles for innovative vaccines and therapeutics.”
The PRINT manufacturing process uses a proprietary roll-to-roll method
that allows Liquidia to produce precisely engineered particles, which
offer safer and more efficient delivery of vaccine and therapeutic drug
products. The capabilities realized as a direct result of this project
will support the advancement of a platform of products, including the
company’s initial vaccine product which is expected to enter clinical
trials next year.
“As an industry, we are on the cusp of great therapeutic advancements in
areas where unmet medical needs still persist,” said Neal Fowler, CEO of
Liquidia Technologies. “An investment such as this plays a critical role
in enabling Liquidia to advance innovative products to the next stage of
development where we will begin to see the true potential for patients.”
http://www.liquidia.com/